Patents by Inventor Jessica Weaver

Jessica Weaver has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-PHOSPHOTYROSINYLATED PROGRAMMED DEATH 1 (PD-1) MONOCLONAL ANTIBODIES, METHODS OF MAKING AND METHODS OF USING THEREOF
    Publication number: 20230331847
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Application
    Filed: September 22, 2022
    Publication date: October 19, 2023
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • Anti-phosphotyrosinylated programmed death 1 (PD-1) monoclonal antibodies, methods of making and methods of using thereof
    Patent number: 11492403
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Grant
    Filed: April 20, 2018
    Date of Patent: November 8, 2022
    Assignees: Dana-Farber Cancer Institute, Inc., Beth Israel Deaconess Medical Center, President and Fellows of Harvard College
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Strauss
  • INJECTION MOLDING TO GENERATE COMPLEX HYDROGEL GEOMETRIES FOR CELL ENCAPSULATION
    Publication number: 20210146010
    Abstract: Provided herein is a cell macroencapsulation device composed of hydrogel in a 3D conformation that optimizes encapsulated cell viability and function when transplanted into a vascularized tissue space. The hydrogel macroencapsulation device is intended to reduce or eliminate immune response to the cell graft, while allowing exchange of encapsulated cell-secreted products, such as insulin. Also described herein is an injection-mold and fabrication process to generate the hydrogel macroencapsulation devices for use in the clinic.
    Type: Application
    Filed: November 18, 2020
    Publication date: May 20, 2021
    Applicant: Arizona Board of Regents on behalf of Arizona State University
    Inventors: Jessica Weaver, Alec McCall, Sarah Brady
  • ANTI-PHOSPHOTYROSINYLATED PD-1 ANTIBODIES AND USES THEREOF
    Publication number: 20200115452
    Abstract: The present invention is based, in part, on the discovery of monoclonal and polyclonal antibodies that specifically bind to phosphorylated PD-1, as well as immunoglobulins, polypeptides, nucleic acids thereof, and methods of using such antibodies for diagnostic, prognostic, and therapeutic purposes.
    Type: Application
    Filed: April 20, 2018
    Publication date: April 16, 2020
    Inventors: Gordon J. Freeman, Vassiliki A. Boussiotis, Xia Bu, Vikram R. Juneja, Arlene H. Sharpe, Nikolaos Patsoukis, Jessica Weaver, Laura Straus
  • MACROPOROUS BIOENGINEERED SCAFFOLDS FOR CELL TRANSPLANTATION
    Publication number: 20130089594
    Abstract: The present invention provides highly porous, biocompatible and biostable scaffold constructs for improving overall cell engraftment, survival, function and long-term viability. These scaffolds can provide mechanical protection to implanted cells, afford retrievability from a subject, and allow for both intra-device vascularization and a means to spatially distribute the cells within the device. The scaffold surface or material may be modified with one or more different adhesion proteins and optionally other biological factors for enhanced cell adherence and viability. Further, the scaffold surface or material may be modified with one or more agents with slow/sustained release characteristics to aid engraftment, survival, function or long-term viability. Implanted cells of the invention may be insulin-producing cells such as islets.
    Type: Application
    Filed: April 12, 2011
    Publication date: April 11, 2013
    Applicants: CONVERGE BIOTECH INC., UNIVERSITY OF MIAMI
    Inventors: Cheryl Stabler Anderson, Eileen Pedraza, Christopher A. Fraker, Peter Buchwald, Norma Sue Kenyon, Luca Inverardi, Antonello Pileggi, Paul Latta, Jeffrey Hubbell, Jessica Weaver, Camillo D. Ricordi